ZEALAND PHARMA
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is ... marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
ZEALAND PHARMA
Industry:
Biopharma Biotechnology Health Care
Founded:
1998-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.zealandpharma.com
Total Employee:
251+
Status:
Active
Contact:
45 88 77 36 00
Total Funding:
1.59 B USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag Mobile Non Scaleable Content Organization Schema
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
ZOE Health Study
ZOE Health Study is a biotechnology research company that offers technology to unlock the secrets of the immune system.
Current Advisors List
Board_member
Board_member
2015-04-01
Board_member
2015-04-01
Board_member
2018-04-01
Advisor
2020-08-01
Board_member
2007-01-01
Current Employees Featured
Andrew Parker Chief Scientific Officer, Executive Vice-President, Head of Research & External Innovation @ Zealand Pharma
Chief Scientific Officer, Executive Vice-President, Head of Research & External Innovation
2016-07-01
Marie Skovgaard Director of Medicinal Chemistry @ Zealand Pharma
Director of Medicinal Chemistry
2016-03-01
Daan Ellens Chairman of the Supervisory Board @ Zealand Pharma
Chairman of the Supervisory Board
Pernille Tofteng Shelton Senior Scientist @ Zealand Pharma
Senior Scientist
2014-01-01
Matt Dallas Chief Financial Officer @ Zealand Pharma
Chief Financial Officer
Lars Hellerung Christiansen Co-Founder @ Zealand Pharma
Co-Founder
1998-01-01
Matthew Nguyen Vice President @ Zealand Pharma
Vice President
2020-04-01
Adam Steensberg Chief Executive Officer @ Zealand Pharma
Chief Executive Officer
2022-03-01
Eva Steiness Founder @ Zealand Pharma
Founder
Dr. Bjarne Due Larsen Founder @ Zealand Pharma
Founder
1998-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-02-10 | Valeritas | Valeritas acquired by Zealand Pharma | 23 M USD |
| 2019-10-23 | Encycle Therapeutics | Encycle Therapeutics acquired by Zealand Pharma | N/A |
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - Zealand Pharma
Oberland Capital
Oberland Capital investment in Post-IPO Debt - Zealand Pharma
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Equity - Zealand Pharma
Idinvest Partners
Idinvest Partners investment in Venture Round - Zealand Pharma
Innovation Capital
Innovation Capital investment in Venture Round - Zealand Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-08 | Beta Bionics | Zealand Pharma investment in Series B - Beta Bionics | 63 M USD |
Key Employee Changes
Official Site Inspections
http://www.zealandpharma.com Semrush global rank: 723.14 K Semrush visits lastest month: 42.66 K
- Host name: 104.47.160.14
- IP address: 104.47.160.14
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Zealand Pharma"
Investors - Zealand Pharma
4 days ago In 2024, we advanced our clinical-stage obesity portfolio, raised significant capital to further invest in our pipeline, and prepared the organization for the next phase of growth. Read …See details»
Zealand Pharma - Wikipedia
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. [1] …See details»
Zealand Pharma - Crunchbase Company Profile
Contact Email info@zealandpharma.com Phone Number 45 88 77 36 00 Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company …See details»
Contact - Zealand Pharma
3.5 The Compliance Hotline may only be used for reporting violations or potential violations in relation to the issues described in section 3.4 that have occurred or most probably will occur in Zealand Pharma's organization, committed for …See details»
Zealand Pharma - LinkedIn
Zealand Pharma announces a transformational, global collaboration and license agreement with Roche to co-develop and co-commercialize our long-acting amylin analog, paving the way to …See details»
Zealand Pharma A/S - Overview, News & Similar companies
Mar 20, 2024 Explore Complete Organization Structure. Is Zealand Pharma A/S your ideal customer? Let us give you the heads up on whether it's a good time to reach out ... Phone …See details»
Zealand Pharma - Wikipedia, den frie encyklopædi
Zealand Pharma A/S er en dansk bioteknologisk forskningsvirksomhed, som designer og udvikler peptidbaseret medicin, hovedsageligt inden for metaboliske sygdomme som for eksempel …See details»
Zealand Pharma A/S (Zealand Pharma A/S) - 药物管线_ …
For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com. Forward looking statements This company announcement contains “forward-looking statements”, as that term is defined …See details»
Zealand Pharma - EQT Group
Do You Want to Know More? We are eager to explore how we can achieve great things together.See details»
Corporate management - About us - Zealand Pharma
Meet the Corporate Management team, responsible for the day-to-day management of Zealand Pharma and view their profiles.See details»
Zealand Pharma and Roche enter collaboration and license …
Mar 12, 2025 Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a …See details»
Careers at Zealand Pharma US - TriNet
For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. …See details»
Zealand Pharma announces that Boehringer receives U.S. FDA …
Oct 8, 2024 Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please …See details»
Zealand Pharma A-S Aktie - finanzen.net
ZEALAND PHARMA A-S AKTIE Profil - hier finden Sie alle Informationen über ZEALAND PHARMA A-S AKTIE wie z.B. Management, Profil, Aktionärsstruktur und Bilanzdaten.See details»
Zealand Pharma Announces Financial Results for the Full Year 2024
Sustainability – building a sustainable organization • In 2024, Zealand Pharma launched a refined sustainability strategy and developed a Climate Change Transition Plan, outlining activities …See details»
Zealand Pharma and Roche enter collaboration and license
Mar 12, 2025 nahmadi@zealandpharma.com. Anna Krassowska, PhD (Investors & Media) Vice President, Investor Relations & Corporate Communications Zealand Pharma …See details»
Our impact - About us - Zealand Pharma
As we pursue our ambition of becoming the world’s best peptide drug discovery and development company, our impact on global health and society continues to increase.See details»
Zealand Pharma announces completion of enrollment in the
4 days ago For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com. Forward looking statements. This press release contains “forward …See details»
Zealand Pharma provides U.S. regulatory update on
Aug 10, 2024 Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, …See details»
Remuneration Report 2022 - Zealand Pharma
Our shareholders have seen a more focused organization that has executed on its promises under some of the most ... zealandpharma.com Zealand Pharma ˜ Remuneration Report 2022 6. …See details»